Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7fd38ff393036b78f4fa402ddeeae2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_700ff9a01db2075489cb7ed87392dc28 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 |
filingDate |
1998-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b0a11a8eb4b9f23e33176fff634a3f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70a7eb6efcb23c3e1505cd5be935a7eb |
publicationDate |
2000-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0983074-A2 |
titleOfInvention |
Non-myeloablative tolerogenic treatment |
abstract |
The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. |
priorityDate |
1997-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |